Wall Street analysts expect that Achaogen (NASDAQ:AKAO) will post ($0.92) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Achaogen’s earnings. The highest EPS estimate is ($0.80) and the lowest is ($1.02). Achaogen reported earnings per share of ($0.51) during the same quarter last year, which would suggest a negative year-over-year growth rate of 80.4%. The company is expected to announce its next earnings report on Monday, May 14th.
According to Zacks, analysts expect that Achaogen will report full-year earnings of ($3.47) per share for the current financial year, with EPS estimates ranging from ($4.22) to ($2.96). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.31) per share, with EPS estimates ranging from ($3.18) to ($1.59). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Achaogen.
Achaogen (NASDAQ:AKAO) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.21). The firm had revenue of $1.87 million during the quarter, compared to the consensus estimate of $1.18 million. Achaogen had a negative net margin of 1,124.10% and a negative return on equity of 83.14%.
A number of brokerages recently weighed in on AKAO. William Blair reaffirmed an “outperform” rating on shares of Achaogen in a research note on Wednesday, February 28th. ValuEngine raised shares of Achaogen from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Zacks Investment Research downgraded shares of Achaogen from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $20.00 target price (down from $29.00) on shares of Achaogen in a research note on Wednesday, February 28th. Finally, Leerink Swann reaffirmed an “outperform” rating on shares of Achaogen in a research note on Sunday, March 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. Achaogen presently has an average rating of “Buy” and an average price target of $23.56.
Shares of AKAO opened at $12.39 on Monday. The company has a market capitalization of $554.15, a P/E ratio of -3.91 and a beta of 1.02. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of 0.08. Achaogen has a 1-year low of $9.83 and a 1-year high of $27.49.
In other Achaogen news, major shareholder Robert W. Duggan purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, February 14th. The shares were purchased at an average cost of $10.96 per share, with a total value of $109,600.00. Following the completion of the purchase, the insider now owns 5,668,310 shares of the company’s stock, valued at approximately $62,124,677.60. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Robert W. Duggan purchased 47,361 shares of the firm’s stock in a transaction on Wednesday, April 4th. The shares were acquired at an average cost of $12.44 per share, for a total transaction of $589,170.84. Following the completion of the purchase, the insider now directly owns 6,411,108 shares of the company’s stock, valued at approximately $79,754,183.52. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 810,717 shares of company stock worth $8,739,717 and have sold 10,089 shares worth $110,576. Company insiders own 8.36% of the company’s stock.
Several hedge funds have recently bought and sold shares of AKAO. Wells Fargo & Company MN raised its stake in shares of Achaogen by 34.3% during the third quarter. Wells Fargo & Company MN now owns 33,213 shares of the biopharmaceutical company’s stock worth $530,000 after acquiring an additional 8,483 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Achaogen by 154.0% during the third quarter. Schwab Charles Investment Management Inc. now owns 122,684 shares of the biopharmaceutical company’s stock worth $1,957,000 after acquiring an additional 74,384 shares in the last quarter. Hikari Power Ltd raised its stake in shares of Achaogen by 100.0% during the fourth quarter. Hikari Power Ltd now owns 60,000 shares of the biopharmaceutical company’s stock worth $644,000 after acquiring an additional 30,000 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new position in shares of Achaogen during the fourth quarter worth approximately $177,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Achaogen during the fourth quarter worth approximately $412,000. 77.37% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This article was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/16/achaogen-akao-expected-to-post-earnings-of-0-92-per-share.html.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Get a free copy of the Zacks research report on Achaogen (AKAO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.